论文部分内容阅读
目的:探讨采用重组组织型纤溶酶原激活物(rtPA)进行静脉溶栓对脑梗死治疗的有效性及安全性,以供临床参考。方法:将我院2009年5月～2011年2月收治的93例脑梗死患者随机分为两组。对照组患者给予低分子右旋糖酐和复方丹参等活血化瘀和营养脑细胞药物进行治疗。观察组患者给予rtPA(0.9mg/kg)进行静脉溶栓治疗。比较两组患者治疗的疗效及并发症,并将结果进行统计学分析。结果:观察组46例,治愈25例,显效12例,总有效率为82.22%;对照组47例,治愈10例,显效10例,总有效率为42.55%,观察组患者疗效明显优于对照组,p<0.05。结论:采用重组组织型纤溶酶原激活物(rtPA)进行静脉溶栓对脑梗死的治疗具有较好的效果,其不良反应较少,值得在临床上推广使用。
Objective: To investigate the efficacy and safety of intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) in the treatment of cerebral infarction for clinical reference. Methods: Ninety-three patients with cerebral infarction admitted to our hospital from May 2009 to February 2011 were randomly divided into two groups. Patients in the control group were treated with low molecular weight dextran and compound salvia miltiorrhiza and other drugs for promoting brain blood circulation and nutrition. Patients in the observation group were given rtPA (0.9 mg / kg) for intravenous thrombolysis. The curative effect and complications of the two groups were compared, and the results were statistically analyzed. Results: In observation group, 46 cases were cured, 25 cases were cured, 12 cases were markedly effective, and the total effective rate was 82.22%. In control group, 47 cases were cured, 10 cases were markedly cured and the total effective rate was 42.55% Group, p <0.05. Conclusion: Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) has a good effect on the treatment of cerebral infarction with less adverse reactions, which is worth popularizing in clinic.